🇺🇸 FDA
Pipeline program

Vedolizumab

MLN0002-3026

Approved small_molecule completed

Quick answer

Vedolizumab for Colitis, Ulcerative is a Approved program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 5 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Colitis, Ulcerative
Phase
Approved
Modality
small_molecule
Status
completed

Clinical trials